MedPath

Study on the treatment of diarrhea-predominant irritable bowel syndrome with Xifenghuashi Granules through changes in intestinal flora

Phase 1
Recruiting
Conditions
diarrhea-predominant irritable bowel syndrome
Registration Number
ITMCTR2100004795
Lead Sponsor
Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Conform to western medical diagnostic criteria of IBS-D;
2. Conform to diagnostic criteria of TCM syndromes of liver depression and spleen deficiency;
3. Aged 18 to 70 years, gender is not limited;
4. Subjects voluntarily participate in the trial and sign informed consent;
5. The process of obtaining informed consent should conform to ethical principles.

Exclusion Criteria

1. Patients with organic gastrointestinal diseases;
2. Patients with severe heart, liver, kidney, respiratory, blood, and endocrine diseases;
3. Patients with mental illness and severe neurosis;
4. Women who are pregnant, breast-feeding or planning to have a pregnancy;
5. Those who have taken antibiotics or probiotics or gastrointestinal motility drugs within 1 month before being included in the trial;
6. Patients who have poor compliance with doctor's orders or are allergic to this medicine;
7. Patients who are participating in other clinical studies.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
intestinal flora;
Secondary Outcome Measures
NameTimeMethod
efficacy index;mental state and quality of life assessment indicators;
© Copyright 2025. All Rights Reserved by MedPath